Deciphering the Relationship Between Janus Kinase -2 (Jak-2) Mutation and Thrombocytopenia

Shawaiz Sanaullah; Ibrahim  Dayan; Abdal Ali Qureshi  Hashmi; Nida  Anjum; Mariam  Ejaz; Ismat   Zhaira; Dua  Zhaira

doi:10.54112/bcsrj.v6i1.1526

Authors

Shawaiz Sanaullah Zohra Institute of Health Sciences, Rawalpindi, Pakistan
Ibrahim Dayan Riphah International University, Rawalpindi, Pakistan
Abdal Ali Qureshi Hashmi Forensic Toxicology University of Lincoln, England, Pakistan
Nida Anjum Abasyn University Islamabad Campus, Pakistan
Mariam Ejaz Faculty of Rehabilitation and Allied Health Sciences, Riphah International University, Islamabad, Pakistan
Ismat Zhaira Faculty of Rehabilitation and Allied Health Sciences, Riphah International University, Islamabad, Pakistan
Dua Zhaira Faculty of Rehabilitation and Allied Health Sciences, Riphah International University, Islamabad, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v6i1.1526

Keywords:

White blood cells, Hemoglobin, Hematocrit, Platelets, Correlation analysis, Statistical significance.

Abstract

Hematological parameters, including white blood cells (WBCs), haemoglobin (HB), hematocrit (HCT), and platelet (PLT) levels, play a crucial role in assessing overall health and disease conditions. Understanding their relationships with various influencing factors is essential for refining diagnostic and prognostic evaluations. Objective: This study aimed to explore the relationships between various haematological parameters, including white blood cells (WBCs), haemoglobin (HB), hematocrit (HCT), and platelet (PLT) levels, and their respective influencing factors. The correlation coefficients (r-values) and p-values were analyzed to determine the strength and statistical significance of these associations. Methods: A correlation analysis was conducted on the haematological parameters. The R-values were calculated to assess the strength and direction of relationships, while the p-values determined the statistical significance. The parameters studied included WBC, HB, HCT, and PLT. The duration of the study was from April 2024 to September 2024. Results: - WBC analysis yielded an R-value of 0.05 and a p-value of 0.034, indicating a positive correlation with statistical significance.- HB analysis showed an r-value of -0.055 and a p-value of 0.604, reflecting a negative correlation that was not statistically significant. - HCT analysis that was also not statistically significant. - PLT analysis produced an R-value of 0.037 and a p-value of 0.727, indicating a negative correlation that was also not statistically significant. Conclusion: The analysis revealed that while the WBCs and AGE showed a statistically significant positive correlation, the other parameters—HB, HCT, and PLT—did not exhibit statistically significant correlations with the variables studied. These findings suggest that the factors investigated have minimal or no meaningful impact on the haematological parameters, warranting further research to identify more significant associations.

Downloads

Download data is not yet available.

References

Pearson H. Genetics: What is a gene? Nature. 2006; 441(7092).

Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Current opinion in genetics & development. 2007;17(1):8-14.

Agashe RP, Lippman SM, Kurzrock R. JAK: not just another kinase. Molecular cancer therapeutics. 2022;21(12):1757-64.

Brunell S, Pettersson Gradin E, Englöf V, Wigertz L, Persson E, Maglio J. Decoding Hormone Interactions: Investigating Health Status Using Hormone Signatures in Blood. 2023.

Iurlo A, Cattaneo D, Bucelli C, Baldini L. New perspectives on polycythemia vera: from diagnosis to therapy. International Journal of Molecular Sciences. 2020;21(16):5805.

Stuart BJ, Viera AJ. Polycythemia vera. American family physician. 2004;69(9):2139-44.

Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythemia vera. Annals of haematology. 2015;94:901-10.

Mititelu A, Onisâi MC, Roșca A, Vlădăreanu AM. Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options. Int J Mol Sci. 2024;25(4).

Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. International journal of haematology. 2013;98:10-23.

Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood advances. 2019;3(23):3829-66.

Adewoye A, Nolan V, Ma Q. Hemostasis and thrombosis. Genetics. 2007;119:U13-U7.

Vannucchi, A. M. ET, al., (2008). Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukaemia, 22(7), 1299-1307.

Tefferi, A., & Pardanani, A. (2006). Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leukemia Research, 30(5), 537-544.

Passamonti, F., Rumi, E., Pietra, D., Elena, C., & Cazzola, M. (2010). The genetic basis of myeloproliferative neoplasms. Haematology/Oncology Clinics of North America, 24(5), 1079-1091.

Tefferi, A., & Vainchenker, W. (2011). Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. Journal of Clinical Oncology, 29(5), 573-582.

C., Terrell, D. R., Arnold, D. M., Buchanan, G., Cines, D. B., Cooper, N., & Vesely, S. K. (2019). American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 3(23), 3829-3866.

Kuter, D. J. (2015). The biology of thrombopoietin and thrombopoietin receptor agonists. International Journal of Hematology, 101(4), 312-323.

Neunert, C., Terrell, D. R., Arnold, D. M., Buchanan, G., Cines, D. B., Cooper, N., & Vesely, S. K. (2019). American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 3(23), 3829-3866.

Segal, J. B., & Powe, N. R. (2006). Prevalence of thrombocytopenia in adults: A systematic review. Journal of the American Medical Association, 295(7), 806-814.

Tripodi, A., & Mannucci, P. M. (2011). The coagulopathy of chronic liver disease. The New England Journal of Medicine, 365(2), 147-156.

Kouri, Y. H., Borkowsky, W., & Boxer, L. A. (2001). Thrombocytopenia in human immunodeficiency virus-infected children. Journal of Pediatrics, 138(6), 879-884.

Hoffbrand, A. V., & Moss, P. A. H. (2016). Essential Haematology (7th ed.). Wiley-Blackwell.

George, J. N., & Raskob, G. E. (2007). Clinical Practice. Immune Thrombocytopenic Purpura. The New England Journal of Medicine, 357(10), 1027-1036.

McCrae, K. R. (2017). Thrombocytopenia in Pregnancy: Differential Diagnosis, Pathogenesis, and Management. Blood Reviews, 31(1), 41-51.

Kaushansky, K., & Levi, M. (2017). Thrombocytopenia in Patients with Cirrhosis: Pathophysiology and Management. Thrombosis Research, 160, 99-105.

Cines, D. B., & Blanchette, V. S. (2002). Immune Thrombocytopenic Purpura. The New England Journal of Medicine, 346(13), 995-1.

Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ. Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry. 2005 Jun 17; 280(24):22788-92.

McLornan D, Percy M, McMullin MF. JAK2 V617F: a single mutation in the myeloproliferative group of disorders. The Ulster Medical Journal. 2006 May; 75(2):112.

Stuart BJ, Viera AJ. Polycythemia vera. American family physician. 2004 May 1; 69(9):2139-44.

Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: Historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021 Dec; 35(12):3339-51.

Policitemia GI. Polycythemia vera: The natural history of 1213 patients followed for 20 years. Annals of Internal Medicine. 1995 Nov 1; 123(9):656-64.

Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ. Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry. 2005 Jun 17; 280(24):22788-92

Izak M, Bussel JB. Management of thrombocytopenia. F1000prime reports. 2014; 6.

Gauer RL, Braun MM. Thrombocytopenia. American family physician. 2012 Mar 15; 85(6):612.